View Older Stories
-
Why Eli Lilly stock is down 3% today: FDA adverse event data explained
-
Enveda Reports Positive Results for ENV-294 in a Phase 1b Clinical Trial of Patients with Moderate-to-Severe Atopic Dermatitis
-
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
-
Evercore ISI on Vaxcyte (PCVX): 'vaccine shakeup, but there's no change to PCV recs...'
-
Evercore Hosts 8th Annual Healthcare Conference, Dec. 2-4, 2025
-
Shattuck Labs to Participate in Upcoming December Investor Conferences
-
Life Sciences, TechBio, and Investment Leaders at Demy-Colton’s BioFuture™ 2025 Suggest Health and Biotech Sectors Show Signs of New Life
-
Evercore ISI Ranked No. 1 in Extel All-America Research Survey for 4th Straight Year
-
BioFuture™ 2025 Explores the Next Era of Innovation, Policy, and Investment in Biopharma
-
Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association’s 85th Scientific Sessions
-
Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile
-
Analysis-Americans hungry for weight-loss drugs grapple with supply and insurance hurdles
-
Evercore ISI Recognized as the #1 Firm in U.S. Equity Research for the Third Consecutive Year
-
Evercore ISI Starts Spyre (SYRE) at Outperform
-
Evercore ISI on Gilead (GILD): 'Gilead isn’t hyping it etc, the conversation flow was us reaching out to Gilead to clarify, rather than Gilead flagging it to everyone'
-
Amgen 'encouraged' by weight-loss drug interim data, shares jump
-
Evercore ISI Downgrades Amylyx Pharmaceuticals inc. (AMLX) to In Line
-
Evercore ISI Starts Fractyl Health Inc (GUTS) at Outperform
-
Frontier Medicines to Participate in Upcoming Investor Conferences
-
Evercore ISI Starts Rapt Therapeutics (RAPT) at Outperform, 'risk reward is very good at these levels'
-
Pharma price cut proposals from US government could be steep, analysts say
-
Gilead drops 11% after lung cancer drug trial fails, analyst says stock is 'overreacting'
-
Analyst says buy the pullback in obesity stocks as today's report refers to old data
-
Evercore ISI Recognized as the Top-Ranked Firm in U.S. Equity Research for the Second Consecutive Year
-
Evercore ISI Upgrades Alkermes (ALKS) to Outperform, 'down 10%? I wouldn’t have thought so'
-
Around 1.8 million Americans received COVID shots last week -IQVIA
-
Evercore ISI Remains Positive on Apellis Pharmaceuticals (APLS)
-
Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
-
Evercore ISI on Pfizer (PFE): 'Hard to ignore the d-dimer findings with Pfizer TFPI'
-
Evercore ISI Upgrades Teva Pharma (TEVA) to Outperform, 'TL1A & pipeline in focus'
-
Evercore's DiFiore on Amylyx Pharmaceuticals inc. (AMLX) ALS Relyvrio Launch: 'I feel very confident in launch and remain very constructive'
-
Evercore ISI Says Gilead Sciences (GILD) Tenofovir Risk 'waning'
-
Evercore Says Cerevel Therapeutics Holdings (CERE) BP Results are 'Very Positive'
-
Bausch Health (BHC): FDA Added Extra Hurdle for Generic Xifaxan - Evercore ISI
-
Inspirna to Present at the Evercore ISI Annual HealthCONx Conference
-
Evercore ISI Recognized as the Top-Ranked Firm in U.S. Equity Research
-
UPDATE: Evercore ISI Downgrades Phathom Pharmaceuticals (PHAT) to In Line
-
Evercore ISI Recognized as the Top Ranked Independent Firm in U.S. Equity Research
-
Moderna (MRNA), BioNTech (BNTX) Hit Session Low Amid Doubt FDA Will Back Vaccine Booster
-
Prometheus Biosciences to Host Virtual R&D Day for Investors on July 28, 2021
-
Prometheus Biosciences to Host Virtual R&D Day for Investors on July 28, 2021
-
Investors, patients await FDA decision on Biogen Alzheimer's drug due Monday
-
Januvia IP an under-the-radar catalyst for Merck (MRK) - Evercore ISI
-
Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference
-
Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference
-
Evercore ISI Starts Atea Pharmaceuticals (AVIR) at Outperform
-
RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences
-
Evercore ISI Starts Arcus Biosciences (RCUS) at Outperform
-
Evercore ISI Recognized as the Top Ranked Independent Firm in U.S. Equity Research
-
Evercore ISI Upgrades Amgen (AMGN) to Outperform

